Dr. Katie Murray and GU oncology nurse practitioner Laura Bauer discuss how multidisciplinary collaboration is becoming increasingly important in managing non–muscle invasive bladder cancer. They highlight how integrating medical oncology teams helps manage intravesical therapies, coordinate treatment logistics, and expand access to newer agents such as gemcitabine/docetaxel, nadofaragene firadenovec, N-803, and mitomycin hydrogel. As treatment options rapidly expand, this team-based model allows urology practices to maintain procedural capacity while ensuring patients receive timely, specialized care.
Belzutifan Moves Earlier in Kidney Cancer Care
Dr. Laurence Albiges outlines how belzutifan is reshaping kidney cancer treatment across disease stages. In the adjuvant setting, adding belzutifan
